Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
BMC Cancer|May 6, 2018
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyEric Raymond, Alba A Brandes, Christian Dittrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerEva Thomas, Josep Tabernero, Monica Fornier, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga, Jonas Bergh, Judith Bliss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJavier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancerStephen Chan, Gilles Romieu, Jens Huober, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Journal of the National Cancer Institute|November 25, 2015
Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide AptamerJessica Gobbo, Guillaume Marcion, Marine Cordonnier, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
BMC Cancer|May 6, 2018
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyEric Raymond, Alba A Brandes, Christian Dittrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerEva Thomas, Josep Tabernero, Monica Fornier, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga, Jonas Bergh, Judith Bliss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJavier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancerStephen Chan, Gilles Romieu, Jens Huober, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Journal of the National Cancer Institute|November 25, 2015
Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide AptamerJessica Gobbo, Guillaume Marcion, Marine Cordonnier, et al.
Pageof 11